{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T09:55:06Z","timestamp":1789034106284,"version":"build-2803163510"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"crossref","award":["1R01CA192627"],"award-info":[{"award-number":["1R01CA192627"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["3P30CA13696"],"award-info":[{"award-number":["3P30CA13696"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001322","name":"South African Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1007\/s10549-020-05889-8","type":"journal-article","created":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T18:45:46Z","timestamp":1598985946000},"page":"861-872","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["A comparison of complete pathologic response rates following neoadjuvant chemotherapy among South African breast cancer patients with and without concurrent HIV infection"],"prefix":"10.1007","volume":"184","author":[{"given":"Sarah","family":"Nietz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1779-1166","authenticated-orcid":false,"given":"Daniel S","family":"O\u2019Neil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oluwatosin","family":"Ayeni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenlong Carl","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen","family":"Joffe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith S","family":"Jacobson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfred I","family":"Neugut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Ruff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Witness","family":"Mapanga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ines","family":"Buccimazza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urishka","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"\u010ca\u010dala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Stopforth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boitumelo","family":"Phakathi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Chirwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herbert","family":"Cubasch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,1]]},"reference":[{"key":"5889_CR1","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1097\/QAI.0b013e3181b563e7","volume":"53","author":"K Harrison","year":"2010","unstructured":"Harrison K, Song R, Zhang X (2010) Life expectancy after HIV diagnosis based on national HIV surveillance data from 25 states, United States. JAIDS J Acquir Immune Defic Syndr 53:124\u2013130. https:\/\/doi.org\/10.1097\/QAI.0b013e3181b563e7","journal-title":"JAIDS J Acquir Immune Defic Syndr"},{"key":"5889_CR2","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1097\/QAI.0000000000000960","volume":"72","author":"A-A Siddiqi","year":"2016","unstructured":"Siddiqi A-A, Irene Hall H, Hu X, Song R (2016) Population-based estimates of life expectancy after hiv diagnosis United States 2008\u20132011. J Acquir Immune Defic Syndr 72:230\u2013236. https:\/\/doi.org\/10.1097\/QAI.0000000000000960","journal-title":"J Acquir Immune Defic Syndr"},{"key":"5889_CR3","doi-asserted-by":"publisher","DOI":"10.1126\/science.1230413","author":"J Bor","year":"2013","unstructured":"Bor J, Herbst AJ, Newell M-L, B\u00e4rnighausen T (2013) Increases in adult life expectancy in rural South Africa: valuing the scale-up of HIV treatment. Science. https:\/\/doi.org\/10.1126\/science.1230413","journal-title":"Science"},{"key":"5889_CR4","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1056\/NEJMra1615896","volume":"378","author":"R Yarchoan","year":"2018","unstructured":"Yarchoan R, Uldrick TS (2018) HIV-associated cancers and related diseases. N Engl J Med 378:1029\u20131041. https:\/\/doi.org\/10.1056\/NEJMra1615896","journal-title":"N Engl J Med"},{"key":"5889_CR5","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1093\/jnci\/djr076","volume":"103","author":"MS Shiels","year":"2011","unstructured":"Shiels MS, Pfeiffer RM, Gail MH et al (2011) Cancer burden in the HIV-infected population in the United States. JNCI J Natl Cancer Inst 103:753\u2013762. https:\/\/doi.org\/10.1093\/jnci\/djr076","journal-title":"JNCI J Natl Cancer Inst"},{"key":"5889_CR6","doi-asserted-by":"publisher","DOI":"10.7326\/M17-2499","author":"MS Shiels","year":"2018","unstructured":"Shiels MS, Islam JY, Rosenberg PS et al (2018) Projected cancer incidence rates and burden of incident cancer cases in HIV-infected adults in the United States through 2030. Ann Intern Med. https:\/\/doi.org\/10.7326\/M17-2499","journal-title":"Ann Intern Med"},{"key":"5889_CR7","unstructured":"UNAIDS (2019) Global HIV & AIDS statistics\u20142019 fact sheet. UNAIDS.\u00a0https:\/\/www.unaids.org\/sites\/default\/files\/media_asset\/UNAIDS_FactSheet_en.pdf. Accessed 19 Dec 2019"},{"key":"5889_CR8","doi-asserted-by":"publisher","first-page":"2732","DOI":"10.1002\/ijc.31722","volume":"143","author":"VA McCormack","year":"2018","unstructured":"McCormack VA, Febvey-Combes O, Ginsburg O, dos-Santos-Silva I (2018) Breast cancer in women living with HIV: a first global estimate. Int J Cancer 143:2732\u20132740. https:\/\/doi.org\/10.1002\/ijc.31722","journal-title":"Int J Cancer"},{"key":"5889_CR9","volume-title":"Global cancer observatory: cancer tomorrow","author":"J Ferlay","year":"2018","unstructured":"Ferlay J, Ervik M, Colombet M et al (2018) Global cancer observatory: cancer tomorrow. International Agency for Research on Cancer, Lyon"},{"key":"5889_CR10","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/S0140-6736(07)61050-2","volume":"370","author":"AE Grulich","year":"2007","unstructured":"Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM (2007) Incidence of cancers in people with HIV\/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 370:59\u201367. https:\/\/doi.org\/10.1016\/S0140-6736(07)61050-2","journal-title":"Lancet"},{"key":"5889_CR11","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1093\/jnci\/djy010","volume":"110","author":"AE Coghill","year":"2018","unstructured":"Coghill AE, Engels EA, Schymura MJ et al (2018) Risk of breast, prostate, and colorectal cancer diagnoses among HIV-infected individuals in the United States. J Natl Cancer Inst 110:959\u2013966. https:\/\/doi.org\/10.1093\/jnci\/djy010","journal-title":"J Natl Cancer Inst"},{"key":"5889_CR12","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1002\/ijc.31537","volume":"143","author":"T Mpunga","year":"2018","unstructured":"Mpunga T, Znaor A, Uwizeye FR et al (2018) A case\u2013control study of HIV infection and cancer in the era of antiretroviral therapy in Rwanda. Int J Cancer 143:1348\u20131355. https:\/\/doi.org\/10.1002\/ijc.31537","journal-title":"Int J Cancer"},{"key":"5889_CR13","doi-asserted-by":"publisher","first-page":"2376","DOI":"10.1200\/JCO.2014.59.5967","volume":"33","author":"AE Coghill","year":"2015","unstructured":"Coghill AE, Shiels MS, Suneja G, Engels EA (2015) Elevated cancer-specific mortality among HIV-infected patients in the United States. J Clin Oncol 33:2376\u20132383. https:\/\/doi.org\/10.1200\/JCO.2014.59.5967","journal-title":"J Clin Oncol"},{"key":"5889_CR14","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.1742","author":"AE Coghill","year":"2019","unstructured":"Coghill AE, Suneja G, Rositch AF et al (2019) HIV infection, cancer treatment regimens, and cancer outcomes among elderly adults in the United States. JAMA Oncol. https:\/\/doi.org\/10.1001\/jamaoncol.2019.1742","journal-title":"JAMA Oncol"},{"key":"5889_CR15","doi-asserted-by":"publisher","first-page":"2868","DOI":"10.1002\/cncr.32158","volume":"125","author":"AE Coghill","year":"2019","unstructured":"Coghill AE, Han X, Suneja G et al (2019) Advanced stage at diagnosis and elevated mortality among US patients with cancer infected with HIV in the National Cancer Data Base. Cancer 125:2868\u20132876. https:\/\/doi.org\/10.1002\/cncr.32158","journal-title":"Cancer"},{"key":"5889_CR16","doi-asserted-by":"publisher","first-page":"2933","DOI":"10.1097\/01.aids.0000433236.55937.cb","volume":"27","author":"AE Coghill","year":"2013","unstructured":"Coghill AE, Newcomb PA, Madeleine MM et al (2013) Contribution of HIV infection to mortality among cancer patients in Uganda. AIDS 27:2933\u20132942. https:\/\/doi.org\/10.1097\/01.aids.0000433236.55937.cb","journal-title":"AIDS"},{"key":"5889_CR17","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.canep.2017.12.007","volume":"52","author":"H Cubasch","year":"2018","unstructured":"Cubasch H, Dickens C, Joffe M et al (2018) Breast cancer survival in Soweto, Johannesburg, South Africa: a receptor-defined cohort of women diagnosed from 2009 to 11. Cancer Epidemiol 52:120\u2013127. https:\/\/doi.org\/10.1016\/j.canep.2017.12.007","journal-title":"Cancer Epidemiol"},{"key":"5889_CR18","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.1002\/cncr.30052","volume":"122","author":"G Suneja","year":"2016","unstructured":"Suneja G, Lin CC, Simard EP et al (2016) Disparities in cancer treatment among patients infected with the human immunodeficiency virus: Cancer Treatment in HIV-Infected Individuals. Cancer 122:2399\u20132407. https:\/\/doi.org\/10.1002\/cncr.30052","journal-title":"Cancer"},{"key":"5889_CR19","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1093\/cid\/ciy373","volume":"67","author":"AF Rositch","year":"2018","unstructured":"Rositch AF, Jiang S, Coghill AE et al (2018) Disparities and determinants of cancer treatment in elderly americans living with human immunodeficiency virus\/AIDS. Clin Infect Dis 67:1904\u20131911. https:\/\/doi.org\/10.1093\/cid\/ciy373","journal-title":"Clin Infect Dis"},{"key":"5889_CR20","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/cei.12814","volume":"187","author":"M Nasi","year":"2017","unstructured":"Nasi M, De Biasi S, Gibellini L et al (2017) Ageing and inflammation in patients with HIV infection. Clin Exp Immunol 187:44\u201352. https:\/\/doi.org\/10.1111\/cei.12814","journal-title":"Clin Exp Immunol"},{"key":"5889_CR21","doi-asserted-by":"publisher","first-page":"R84","DOI":"10.1186\/bcr3478","volume":"15","author":"VA McCormack","year":"2013","unstructured":"McCormack VA, Joffe M, van den Berg E et al (2013) Breast cancer receptor status and stage at diagnosis in over 1,200 consecutive public hospital patients in Soweto, South Africa: a case series. Breast Cancer Res 15:R84. https:\/\/doi.org\/10.1186\/bcr3478","journal-title":"Breast Cancer Res"},{"key":"5889_CR22","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0535","author":"DS O\u2019Neil","year":"2018","unstructured":"O\u2019Neil DS, Nietz S, Buccimazza I et al (2018) Neoadjuvant chemotherapy use for nonmetastatic breast cancer at five public south african hospitals and impact on time to initial cancer therapy. Oncologist. https:\/\/doi.org\/10.1634\/theoncologist.2018-0535","journal-title":"Oncologist"},{"key":"5889_CR23","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/j.jamcollsurg.2016.08.541","volume":"223","author":"JJ Mohiuddin","year":"2016","unstructured":"Mohiuddin JJ, Deal AM, Carey LA et al (2016) Neoadjuvant systemic therapy utilization for younger patients with breast cancer treated in different types of cancer centers across the United States. J Am Coll Surg 223:717\u2013728.e4. https:\/\/doi.org\/10.1016\/j.jamcollsurg.2016.08.541","journal-title":"J Am Coll Surg"},{"key":"5889_CR24","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","volume":"384","author":"P Cortazar","year":"2014","unstructured":"Cortazar P, Zhang L, Untch M et al (2014) Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 384:164\u2013172. https:\/\/doi.org\/10.1016\/S0140-6736(13)62422-8","journal-title":"Lancet"},{"key":"5889_CR25","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-3492","author":"LM Spring","year":"2020","unstructured":"Spring LM, Fell G, Arfe A et al (2020) Pathological complete response after neoadjuvant chemotherapy and impact on breast cancer recurrence and survival: a comprehensive meta-analysis. Clin Cancer Res. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-3492","journal-title":"Clin Cancer Res"},{"key":"5889_CR26","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.2535","author":"D Yee","year":"2020","unstructured":"Yee D, DeMichele AM, Yau C et al (2020) Association of event-free and distant recurrence-free survival with individual-level pathologic complete response in neoadjuvant treatment of stages 2 and 3 breast cancer: three-year follow-up analysis for the I-SPY2 adaptively randomized clinical trial. JAMA Oncol. https:\/\/doi.org\/10.1001\/jamaoncol.2020.2535","journal-title":"JAMA Oncol"},{"key":"5889_CR27","volume-title":"The world factbook 2018","author":"Central Intelligence Agency","year":"2018","unstructured":"Central Intelligence Agency (2018) The world factbook 2018. Central Intelligence Agency, Washington, DC"},{"key":"5889_CR28","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/S0140-6736(09)60951-X","volume":"374","author":"H Coovadia","year":"2009","unstructured":"Coovadia H, Jewkes R, Barron P et al (2009) The health and health system of South Africa: historical roots of current public health challenges. Lancet 374:817\u2013834. https:\/\/doi.org\/10.1016\/S0140-6736(09)60951-X","journal-title":"Lancet"},{"key":"5889_CR29","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1007\/s00268-017-4187-0","volume":"42","author":"WC Coetzee","year":"2018","unstructured":"Coetzee WC, Apffelstaedt JP, Zeeman T, Du Plessis M (2018) Disparities in breast cancer: private patients have better outcomes than public patients. World J Surg 42:727\u2013735. https:\/\/doi.org\/10.1007\/s00268-017-4187-0","journal-title":"World J Surg"},{"key":"5889_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/JGO.19.11000","volume":"5","author":"DS O\u2019Neil","year":"2019","unstructured":"O\u2019Neil DS, Chen WC, Ayeni O et al (2019) Breast cancer care quality in South Africa\u2019s public health system: an evaluation using American Society of Clinical Oncology\/National Quality Forum measures. J Glob Oncol 5:1\u20136","journal-title":"J Glob Oncol"},{"key":"5889_CR31","volume-title":"The fifth South African national HIV prevalence, incidence, behavior and communication survey, 2017: HIV impact assessment summary report","author":"Human Sciences Research Council","year":"2018","unstructured":"Human Sciences Research Council (2018) The fifth South African national HIV prevalence, incidence, behavior and communication survey, 2017: HIV impact assessment summary report. HSRC Press, Cape Town"},{"key":"5889_CR32","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1200\/JGO.2015.002675","volume":"3","author":"H Cubasch","year":"2016","unstructured":"Cubasch H, Ruff P, Joffe M et al (2016) South African breast cancer and HIV outcomes study: methods and baseline assessment. J Glob Oncol 3:114\u2013124. https:\/\/doi.org\/10.1200\/JGO.2015.002675","journal-title":"J Glob Oncol"},{"key":"5889_CR33","doi-asserted-by":"publisher","first-page":"8331","DOI":"10.1200\/JCO.2005.01.2898","volume":"23","author":"R Rouzier","year":"2005","unstructured":"Rouzier R, Pusztai L, Delaloge S et al (2005) Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancer. J Clin Oncol 23:8331\u20138339. https:\/\/doi.org\/10.1200\/JCO.2005.01.2898","journal-title":"J Clin Oncol"},{"key":"5889_CR34","doi-asserted-by":"publisher","first-page":"3501","DOI":"10.1245\/s10434-016-5277-1","volume":"23","author":"J Vila","year":"2016","unstructured":"Vila J, Mittendorf EA, Farante G et al (2016) Nomograms for predicting axillary response to neoadjuvant chemotherapy in clinically node-positive patients with breast cancer. Ann Surg Oncol 23:3501\u20133509. https:\/\/doi.org\/10.1245\/s10434-016-5277-1","journal-title":"Ann Surg Oncol"},{"key":"5889_CR35","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1186\/s12885-018-4925-1","volume":"18","author":"P Gass","year":"2018","unstructured":"Gass P, Lux MP, Rauh C et al (2018) Prediction of pathological complete response and prognosis in patients with neoadjuvant treatment for triple-negative breast cancer. BMC Cancer 18:1051. https:\/\/doi.org\/10.1186\/s12885-018-4925-1","journal-title":"BMC Cancer"},{"key":"5889_CR36","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1200\/JCO.2008.17.9952","volume":"27","author":"S Dawood","year":"2009","unstructured":"Dawood S, Broglio K, Kau S-W et al (2009) Triple receptor-negative breast cancer: the effect of race on response to primary systemic treatment and survival outcomes. J Clin Oncol 27:220\u2013226. https:\/\/doi.org\/10.1200\/JCO.2008.17.9952","journal-title":"J Clin Oncol"},{"key":"5889_CR37","doi-asserted-by":"publisher","first-page":"4168","DOI":"10.1002\/cncr.25296","volume":"116","author":"M Chavez-Macgregor","year":"2010","unstructured":"Chavez-Macgregor M, Litton J, Chen H et al (2010) Pathologic complete response in breast cancer patients receiving anthracycline- and taxane-based neoadjuvant chemotherapy: evaluating the effect of race\/ethnicity. Cancer 116:4168\u20134177. https:\/\/doi.org\/10.1002\/cncr.25296","journal-title":"Cancer"},{"key":"5889_CR38","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1007\/s10549-015-3350-2","volume":"150","author":"JR Tichy","year":"2015","unstructured":"Tichy JR, Deal AM, Anders CK et al (2015) Race, response to chemotherapy, and outcome within clinical breast cancer subtypes. Breast Cancer Res Treat 150:667\u2013674. https:\/\/doi.org\/10.1007\/s10549-015-3350-2","journal-title":"Breast Cancer Res Treat"},{"key":"5889_CR39","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s10549-016-3918-5","volume":"159","author":"ET Warner","year":"2016","unstructured":"Warner ET, Ballman KV, Strand C et al (2016) Impact of race, ethnicity, and BMI on achievement of pathologic complete response following neoadjuvant chemotherapy for breast cancer: a pooled analysis of four prospective alliance clinical trials (A151426). Breast Cancer Res Treat 159:109\u2013118. https:\/\/doi.org\/10.1007\/s10549-016-3918-5","journal-title":"Breast Cancer Res Treat"},{"key":"5889_CR40","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1634\/theoncologist.2012-0169","volume":"17","author":"E Del Fabbro","year":"2012","unstructured":"Del Fabbro E, Parsons H, Warneke CL et al (2012) The relationship between body composition and response to neoadjuvant chemotherapy in women with operable breast cancer. Oncologist 17:1240\u20131245. https:\/\/doi.org\/10.1634\/theoncologist.2012-0169","journal-title":"Oncologist"},{"key":"5889_CR41","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s10549-015-3287-5","volume":"150","author":"C Fontanella","year":"2015","unstructured":"Fontanella C, Lederer B, Gade S et al (2015) Impact of body mass index on neoadjuvant treatment outcome: a pooled analysis of eight prospective neoadjuvant breast cancer trials. Breast Cancer Res Treat 150:127\u2013139. https:\/\/doi.org\/10.1007\/s10549-015-3287-5","journal-title":"Breast Cancer Res Treat"},{"key":"5889_CR42","doi-asserted-by":"publisher","first-page":"e119","DOI":"10.1016\/j.clbc.2016.02.018","volume":"16","author":"T Erbes","year":"2016","unstructured":"Erbes T, Stickeler E, R\u00fccker G et al (2016) BMI and pathologic complete response to neoadjuvant chemotherapy in breast cancer: a study and meta-analysis. Clin Breast Cancer 16:e119\u2013132. https:\/\/doi.org\/10.1016\/j.clbc.2016.02.018","journal-title":"Clin Breast Cancer"},{"key":"5889_CR43","first-page":"20","volume":"00","author":"M Picon-Ruiz","year":"2017","unstructured":"Picon-Ruiz M, Morata-Tarifa C, Valle-Goffin JJ et al (2017) Obesity and adverse breast cancer risk and outcome: mechanistic insights and strategies for intervention. CA Cancer J Clin 00:20","journal-title":"CA Cancer J Clin"},{"key":"5889_CR44","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1001\/jamaoncol.2018.0137","volume":"4","author":"BJ Caan","year":"2018","unstructured":"Caan BJ, Feliciano EMC, Prado CM et al (2018) Association of muscle and adiposity measured by computed tomography with survival in patients with nonmetastatic breast cancer. JAMA Oncol 4:798\u2013804. https:\/\/doi.org\/10.1001\/jamaoncol.2018.0137","journal-title":"JAMA Oncol"},{"key":"5889_CR45","doi-asserted-by":"publisher","first-page":"9563","DOI":"10.2147\/CMAR.S216034","volume":"11","author":"C Omarini","year":"2019","unstructured":"Omarini C, Palumbo P, Pecchi A et al (2019) Predictive role of body composition parameters in operable breast cancer patients treated with neoadjuvant chemotherapy. Cancer Manage Res 11:9563\u20139569. https:\/\/doi.org\/10.2147\/CMAR.S216034","journal-title":"Cancer Manage Res"},{"key":"5889_CR46","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/S1470-2045(17)30904-X","volume":"19","author":"C Denkert","year":"2018","unstructured":"Denkert C, von Minckwitz G, Darb-Esfahani S et al (2018) Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol 19:40\u201350. https:\/\/doi.org\/10.1016\/S1470-2045(17)30904-X","journal-title":"Lancet Oncol"},{"key":"5889_CR47","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s40425-016-0165-6","volume":"4","author":"SE Stanton","year":"2016","unstructured":"Stanton SE, Disis ML (2016) Clinical significance of tumor-infiltrating lymphocytes in breast cancer. J Immunother Cancer 4:59. https:\/\/doi.org\/10.1186\/s40425-016-0165-6","journal-title":"J Immunother Cancer"},{"key":"5889_CR48","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1001\/jamaoncol.2015.0830","volume":"1","author":"R Salgado","year":"2015","unstructured":"Salgado R, Denkert C, Campbell C et al (2015) Tumor-infiltrating lymphocytes and associations with pathological complete response and event-free survival in HER2-positive early-stage breast cancer treated with lapatinib and trastuzumab: a secondary analysis of the NeoALTTO trial. JAMA Oncol 1:448\u2013454. https:\/\/doi.org\/10.1001\/jamaoncol.2015.0830","journal-title":"JAMA Oncol"},{"key":"5889_CR49","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1158\/2326-6066.CIR-14-0133","volume":"3","author":"H Wimberly","year":"2015","unstructured":"Wimberly H, Brown JR, Schalper K et al (2015) PD-L1 Expression correlates with tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy in breast cancer. Cancer Immunol Res 3:326\u2013332. https:\/\/doi.org\/10.1158\/2326-6066.CIR-14-0133","journal-title":"Cancer Immunol Res"},{"key":"5889_CR50","doi-asserted-by":"publisher","first-page":"e0152500","DOI":"10.1371\/journal.pone.0152500","volume":"11","author":"Y Mao","year":"2016","unstructured":"Mao Y, Qu Q, Chen X et al (2016) The prognostic value of tumor-infiltrating lymphocytes in breast cancer: a systematic review and meta-analysis. PLoS ONE 11:e0152500. https:\/\/doi.org\/10.1371\/journal.pone.0152500","journal-title":"PLoS ONE"},{"key":"5889_CR51","doi-asserted-by":"publisher","first-page":"2959","DOI":"10.1200\/JCO.2013.55.0491","volume":"32","author":"S Adams","year":"2014","unstructured":"Adams S, Gray RJ, Demaria S et al (2014) Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol 32:2959","journal-title":"J Clin Oncol"},{"key":"5889_CR52","first-page":"51","volume-title":"Advances in immunology","author":"MM Lederman","year":"2013","unstructured":"Lederman MM, Funderburg NT, Sekaly RP et al (2013) Residual immune dysregulation syndrome in treated HIV infection. Advances in immunology. Elsevier, Amsterdam, pp 51\u201383"},{"key":"5889_CR53","doi-asserted-by":"publisher","first-page":"473","DOI":"10.2217\/bmm.15.13","volume":"9","author":"JG Taylor","year":"2015","unstructured":"Taylor JG, Liapis K, Gribben JG (2015) The role of the tumor microenvironment in HIV-associated lymphomas. Biomark Med 9:473\u2013482. https:\/\/doi.org\/10.2217\/bmm.15.13","journal-title":"Biomark Med"},{"key":"5889_CR54","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1097\/QAD.0000000000000780","volume":"29","author":"C Chao","year":"2015","unstructured":"Chao C, Xu L, Silverberg M et al (2015) Stromal immune infiltration in HIV-related diffuse large B-cell lymphoma is associated with HIV disease history and patient survival. AIDS 29:1943\u20131951. https:\/\/doi.org\/10.1097\/QAD.0000000000000780","journal-title":"AIDS"},{"key":"5889_CR55","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1007\/s00262-018-2138-8","volume":"67","author":"V Varki","year":"2018","unstructured":"Varki V, Ioffe OB, Bentzen SM et al (2018) PD-L1, B7\u2013H3, and PD-1 expression in immunocompetent vs. immunosuppressed patients with cutaneous squamous cell carcinoma. Cancer Immunol Immunother CII 67:805\u2013814. https:\/\/doi.org\/10.1007\/s00262-018-2138-8","journal-title":"Cancer Immunol Immunother CII"},{"key":"5889_CR56","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.lungcan.2018.06.028","volume":"123","author":"KA Scilla","year":"2018","unstructured":"Scilla KA, Zandberg DP, Bentzen SM et al (2018) Case-control study of PD-1, PD-L1 and B7\u2013H3 expression in lung cancer patients with and without human immunodeficiency virus (HIV) infection. Lung Cancer 123:87\u201390. https:\/\/doi.org\/10.1016\/j.lungcan.2018.06.028","journal-title":"Lung Cancer"},{"key":"5889_CR57","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1093\/annonc\/mdu191","volume":"25","author":"HR Ali","year":"2014","unstructured":"Ali HR, Provenzano E, Dawson S-J et al (2014) Association between CD8+ T-cell infiltration and breast cancer survival in 12 439 patients. Ann Oncol 25:1536\u20131543. https:\/\/doi.org\/10.1093\/annonc\/mdu191","journal-title":"Ann Oncol"},{"key":"5889_CR58","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1146\/annurev-med-042909-093756","volume":"62","author":"SG Deeks","year":"2011","unstructured":"Deeks SG (2011) HIV infection, inflammation, immunosenescence, and aging. Annu Rev Med 62:141\u2013155. https:\/\/doi.org\/10.1146\/annurev-med-042909-093756","journal-title":"Annu Rev Med"},{"key":"5889_CR59","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1146\/annurev-med-121211-091527","volume":"64","author":"CA Gilbert","year":"2013","unstructured":"Gilbert CA, Slingerland JM (2013) Cytokines, obesity, and cancer: new insights on mechanisms linking obesity to cancer risk and progression. Annu Rev Med 64:45\u201357. https:\/\/doi.org\/10.1146\/annurev-med-121211-091527","journal-title":"Annu Rev Med"},{"key":"5889_CR60","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1159\/000458443","volume":"40","author":"T Welz","year":"2017","unstructured":"Welz T, Wyen C, Hensel M (2017) Drug interactions in the treatment of malignancy in HIV-infected patients. Oncol Res Treat 40:120\u2013127. https:\/\/doi.org\/10.1159\/000458443","journal-title":"Oncol Res Treat"},{"key":"5889_CR61","doi-asserted-by":"publisher","first-page":"71","DOI":"10.3389\/fphar.2016.00071","volume":"7","author":"M Berretta","year":"2016","unstructured":"Berretta M, Caraglia M, Martellotta F et al (2016) Drug-drug interactions based on pharmacogenetic profile between highly active antiretroviral therapy and antiblastic chemotherapy in cancer patients with HIV infection. Front Pharmacol 7:71. https:\/\/doi.org\/10.3389\/fphar.2016.00071","journal-title":"Front Pharmacol"},{"key":"5889_CR62","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.critrevonc.2008.10.013","volume":"72","author":"N Mounier","year":"2009","unstructured":"Mounier N, Katlama C, Costagliola D et al (2009) Drug interactions between antineoplastic and antiretroviral therapies: Implications and management for clinical practice. Crit Rev Oncol Hematol 72:10\u201320. https:\/\/doi.org\/10.1016\/j.critrevonc.2008.10.013","journal-title":"Crit Rev Oncol Hematol"},{"key":"5889_CR63","doi-asserted-by":"publisher","first-page":"e0188379","DOI":"10.1371\/journal.pone.0188379","volume":"12","author":"V Singano","year":"2017","unstructured":"Singano V, Amberbir A, Garone D et al (2017) The burden of gynecomastia among men on antiretroviral therapy in Zomba, Malawi. PLoS ONE 12:e0188379. https:\/\/doi.org\/10.1371\/journal.pone.0188379","journal-title":"PLoS ONE"},{"key":"5889_CR64","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.4102\/sajhivmed.v20i1.1017","volume":"20","author":"JL Dunlop","year":"2019","unstructured":"Dunlop JL, Slemming W, Schnippel K et al (2019) Breast abnormalities in adolescents receiving antiretroviral therapy. S Afr J HIV Med 20:1017. https:\/\/doi.org\/10.4102\/sajhivmed.v20i1.1017","journal-title":"S Afr J HIV Med"},{"key":"5889_CR65","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1186\/s12879-019-4332-5","volume":"19","author":"S Shawarira-Bote","year":"2019","unstructured":"Shawarira-Bote S, Shamu T, Chimbetete C (2019) Gynecomastia in HIV-positive adult men receiving efavirenz-based antiretroviral therapy at Newlands clinic, Harare, Zimbabwe. BMC Infect Dis 19:715. https:\/\/doi.org\/10.1186\/s12879-019-4332-5","journal-title":"BMC Infect Dis"},{"key":"5889_CR66","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1111\/j.1468-1293.2010.00831.x","volume":"11","author":"MJ Sikora","year":"2010","unstructured":"Sikora MJ, Rae JM, Johnson MD, Desta Z (2010) Efavirenz directly modulates estrogen receptor and induces breast cancer cell growth. HIV Med 11:603\u2013607. https:\/\/doi.org\/10.1111\/j.1468-1293.2010.00831.x","journal-title":"HIV Med"},{"key":"5889_CR67","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-016-2652-z","author":"X Jin","year":"2016","unstructured":"Jin X, Jiang Y-Z, Chen S et al (2016) A nomogram for predicting pathological complete response in patients with human epidermal growth factor receptor 2 negative breast cancer. BMC Cancer. https:\/\/doi.org\/10.1186\/s12885-016-2652-z","journal-title":"BMC Cancer"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-020-05889-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-020-05889-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-020-05889-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:15:12Z","timestamp":1630455312000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-020-05889-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,1]]},"references-count":67,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["5889"],"URL":"https:\/\/doi.org\/10.1007\/s10549-020-05889-8","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,1]]},"assertion":[{"value":"22 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Dr. Neugut has received consulting fees from Otsuka, UBC, Hospira and EHE International. Dr. Ruff has received honoraria from Sanofi, Amgen, and Roche and research funding from Amgen, Sanofi, Merck, Novartis. All other authors declare they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional review board of Columbia University in New York City and the human research ethics committees of the University of Witwatersrand in Johannesburg and the University of KwaZulu Natal in Durban and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"This article does not contain any studies with animals performed by any of the authors.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human and animal participants"}}]}}